122 related articles for article (PubMed ID: 30266252)
21. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
Chang H; Samiee S; Yi QL
Leuk Lymphoma; 2006 Jan; 47(1):43-7. PubMed ID: 16321826
[TBL] [Abstract][Full Text] [Related]
22. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostic Value of CD27 Antigen in Patients with Multiple Myeloma].
Wang H; Liu L; Liu F; Chen LJ; Qu XY; Li JY; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1069-1073. PubMed ID: 28823270
[TBL] [Abstract][Full Text] [Related]
24. Fatal cerebral hemorrhage in a patient with CD19-positive IgM-producing aggressive plasma cell myeloma, hyperviscosity syndrome and cryoglobulinemia.
Alatoom A; Elsabrouty R; Willis J; Boils C; Sarode R; Hashim I; Wang HY
Int J Clin Exp Pathol; 2009; 2(5):498-507. PubMed ID: 19294010
[TBL] [Abstract][Full Text] [Related]
25. Atypical IgM multiple myeloma with deletion of c-MAF.
Juárez Salcedo LM; López Rubio M; Gil Fernández JJ; Garcia-Suarez J; Magro E; Arranz E; Gutiérrez Jomarrón I; Marcellini Antonio S; Blasco A; Burgaleta C
Int J Lab Hematol; 2015 Oct; 37(5):686-9. PubMed ID: 25996654
[TBL] [Abstract][Full Text] [Related]
26. Multiple myeloma.
Harousseau JL; Shaughnessy J; Richardson P
Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.
Ryu D; Kim HJ; Joung JG; Lee HO; Bae JS; Kim SJ; Kim H; Park WY; Kim K
Oncotarget; 2016 Jul; 7(30):47127-47133. PubMed ID: 27223072
[TBL] [Abstract][Full Text] [Related]
28. [IgM type multiple myeloma expressing various surface adhesion molecules and demonstrating an aggressive clinical course].
Hirayama Y; Sakamaki S; Tsuji Y; Sagawa T; Chiba H; Matsunaga T; Kato J; Niitsu Y
Rinsho Ketsueki; 2003 Sep; 44(9):957-61. PubMed ID: 14577317
[TBL] [Abstract][Full Text] [Related]
29. [Influence of CD117 Expression on Response of Multiple Myeloma Patients to Chemotherapy].
Tang HL; Shu MM; Dong BX; Gu HT; Liang R; Bai QX; Yang L; Zhang T; Gao GX; Chen XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1346-51. PubMed ID: 26524035
[TBL] [Abstract][Full Text] [Related]
30. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
31. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome.
An G; Xu Y; Shi L; Zou D; Deng S; Sui W; Xie Z; Hao M; Chang H; Qiu L
Leuk Res; 2013 Oct; 37(10):1251-7. PubMed ID: 23927993
[TBL] [Abstract][Full Text] [Related]
32. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
[TBL] [Abstract][Full Text] [Related]
33. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis of a difficult to differentiate case of early-onset hyperviscosity syndrome caused by IgM type multiple myeloma: a case report.
Yoshimura T; Hayashi Y; Shimizu K; Yagi N; Tsutsumi M; Nakaya Y; Fuseya H; Horiuchi M; Yoshida M; Nakao T; Inoue T; Yamane T
Int J Hematol; 2020 Nov; 112(5):741-745. PubMed ID: 32572827
[TBL] [Abstract][Full Text] [Related]
35. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies.
Kraj M; Pogłód R; Kopeć-Szlezak J; Sokołowska U; Woźniak J; Kruk B
Leuk Lymphoma; 2004 Nov; 45(11):2281-9. PubMed ID: 15512818
[TBL] [Abstract][Full Text] [Related]
36. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
37. Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system.
Murase T; Inagaki A; Masaki A; Fujii K; Narita T; Ri M; Hanamura I; Iida S; Inagaki H
J Clin Exp Hematop; 2019 Sep; 59(3):135-139. PubMed ID: 31391406
[TBL] [Abstract][Full Text] [Related]
38. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.
Paul E; Sutlu T; Deneberg S; Alici E; Björkstrand B; Jansson M; Lerner R; Wallblom A; Gahrton G; Nahi H
Oncol Rep; 2009 Jul; 22(1):137-42. PubMed ID: 19513515
[TBL] [Abstract][Full Text] [Related]
39. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
40. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
